Sorafenib

Description

Sorafenib · CAS 284461-73-0 · C21H16ClF3N4O3. UNII 9ZOQ3TZI87. Melting Point: 187-226; Melting Point: 205.6 °C; Solubility: < 0.01 g/L.

Identification

CAS Registry Number	284461-73-0
PubChem CID	216239
Molecular formula	C21H16ClF3N4O3
IUPAC name	4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
UNII (FDA)	9ZOQ3TZI87

Computed Descriptors

Molecular Weight	464.8
XLogP3	4.1
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	7
Rotatable Bond Count	5
Exact Mass	464.0863026
Monoisotopic Mass	464.0863026
Topological Polar Surface Area	92.4
Heavy Atom Count	32
Formal Charge	0

Physical & Chemical Properties

Melting Point	187-226
Melting Point	205.6 °C
Solubility	< 0.01 g/L
Solubility	1.71e-03 g/L
LogP	3.8

Physical description & handling notes

• Solid
• White solid
• Stable if stored as directed; avoid strong oxidizing agents. /Sorafenib tosylate/
• Dangerous products of decomposition: thermal ecomposition may produce toxic gases such as carbon monoxide, carbon dioxide, and nitrogen oxides. /Sorafenib tosylate/
• White to yellowish or brownish solid. Practically insoluble in aqueous media, slightly soluble in ethanol and soluble in PEG 400 /Sorafenib tosylate/
• Oral: Tablets, film-coated: 200 mg (of sorafenib) Nexavar (Bayer, comarketed by Onyx). /Sorafenib tosylate/

GHS Hazard Classification

Reported hazard statements	H351 (40%), H360 (40%), H361 (40%), H362 (60%), H372 (60%), H400 (40%), H402 (20%), H410 (60%)

Documented Uses

• Antineoplastic Agents; Protein Kinase Inhibitors
• THERAPEUTIC CATEGORY: Antineoplastic
• Use (kg; approx.) in Germany (2009): >250
• Use (kg; exact) in Germany (2009): 454
• Consumption (g per capita; approx.) in Germany (2009): 0.00305
• Consumption (g per capita; exact) in Germany (2009): 0.00554

Synonyms

Sorafenib; 284461-73-0; BAY 43-9006; sorafenibum; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; DTXSID7041128; BAY-43-9006; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; 9ZOQ3TZI87; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; BAY 439006; BAY-439006; CHEBI:50924; L01XE05

Frequently Asked Questions

What are the CAS number and molecular formula of Sorafenib?

CAS 284461-73-0; molecular formula C21H16ClF3N4O3; molecular weight — g/mol.

What other names is Sorafenib known by?

Sorafenib, 284461-73-0, BAY 43-9006, sorafenibum, 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide, 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide.

Is Sorafenib classified as hazardous?

Hazard statements reported: H351, H360, H361, H362, H372.

What are the key physical properties of Sorafenib?

Melting Point: 187-226; Melting Point: 205.6 °C; Solubility: < 0.01 g/L; Solubility: 1.71e-03 g/L.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.